2016
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression
Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA. An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell 2016, 30: 432-443. PMID: 27593345, PMCID: PMC5154333, DOI: 10.1016/j.ccell.2016.08.002.Peer-Reviewed Original ResearchConceptsBladder cancer metastasisCancer metastasisLymph node metastasisPoor clinical outcomeTumor-associated macrophagesPrimary tumor growthPotential therapeutic targetOsteopontin expression correlatesNode metastasisClinical outcomesPrimary tumorCD44 axisTherapeutic targetTumor aggressivenessMetastasisTumor growthExpression correlatesTumor cellsRac-GEF Tiam1Osteopontin bindsMetastasis suppressionRac1 axisTumorsCD44RhoGDI2
2012
Neuropilin-1 Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment
Yaqoob U, Cao S, Shergill U, Jagavelu K, Geng Z, Yin M, de Assuncao TM, Cao Y, Szabolcs A, Thorgeirsson S, Schwartz M, Yang JD, Ehman R, Roberts L, Mukhopadhyay D, Shah VH. Neuropilin-1 Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment. Cancer Research 2012, 72: 4047-4059. PMID: 22738912, PMCID: PMC3421041, DOI: 10.1158/0008-5472.can-11-3907.Peer-Reviewed Original ResearchConceptsFibronectin fibril assemblyTumor growthTumor microenvironmentNeuropilin-1Fibril assemblyStromal myofibroblastsNonreceptor tyrosine kinase c-AblTyrosine kinase c-AblHuman cancer specimensNew molecular mechanismCancer cell invasionNRP-1 levelsSerine 612Intracellular associationExtracellular domainMatrix stiffnessMolecular mechanismsC-AblGenetic depletionMatrix proteinsCell invasionClinical outcomesCancer specimensTherapeutic targetingAntibody neutralization
2008
Integrin Agonists as Adjuvants in Chemotherapy for Melanoma
Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF, Sanders JM, Swenson S, Markland F, Conaway MR, Theodorescu D. Integrin Agonists as Adjuvants in Chemotherapy for Melanoma. Clinical Cancer Research 2008, 14: 6193-6197. PMID: 18829498, DOI: 10.1158/1078-0432.ccr-08-1285.Peer-Reviewed Original ResearchConceptsMelanoma linesExtracellular matrixMetastatic melanomaM21 tumorsTherapeutic responseImmunodeficient miceTumor volumeChemotherapyClonal growth assaysTherapy resistanceTumor growthHuman melanomaChemotherapeutic efficacyMelanomaTumor cellsDrug 1Survival assaysM21 cellsM21 melanomaSmall nestsIntegrin agonistsIntegrin-dependent adhesionTumorsMiceSnake venom